Prosigna

Prosigna

Now included in the International Clinical Practice Guidelines, Prosigna by Nanostring detects early stage breast cancer in patients through a highly accurate, FDA-approved risk assessment test. With the use of the PAM50 gene signature to translate tumour biology into a patient’s individualised prognostic score, Prosigna also identifies the patient’s 10-year risk of distant recurrence and intrinsic molecular subtype.

Accreditation

Benefits

  • FDA-approved
  • Predicts the possibility of cancer recurrence over the next 10 years
  • Informs decision about cancer treatment after surgery
  • Helps healthcare professionals decide if hormone therapy alone is sufficient

Process

The test does not require additional surgery and can be performed on cancer tissue specimen preserved from original surgeries.

Results will be released within 10 business days upon receipt of tissue specimen.

Downloads

  • FDA-approved
  • Predicts the possibility of cancer recurrence over the next 10 years
  • Informs decision about cancer treatment after surgery
  • Helps healthcare professionals decide if hormone therapy alone is sufficient
  • Post-menopausal women with newly diagnosed, early stage invasive breast cancer treated with endocrine therapy
  • Women who are hormone receptor positive (estrogen or progesterone)
  • Women who are lymph-node negative or lymph node-positive

The test does not require additional surgery and can be performed on cancer tissue specimen preserved from original surgeries.

Results will be released within 10 business days upon receipt of tissue specimen.